Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche | Contract Pharma
Breaking News, Promotions & Moves

Roche

Janet Hammond, M.D., Ph.D., has been appointed vice president of Translational Medicine – Virology in Pharmaceutical Research and Early Development (pRED) at Roche. Dr. Hammond will report to Jacques Banchereau, Ph.D., Discovery and Translational Area (DTA) head for Inflammation and Virology, and chief scientific officer at Nutley. She will be responsible for driving strategy and implementation of early clinical development for the Virology DTA.

Dr. Hammond has 13 years of experience in the pharmaceutical industry. Prior to joining the company, Dr. Hammond served as chief medical officer and senior vice president of Global Medical Affairs at Valeant Pharmaceuticals, where she was responsible for medical affairs and worldwide pharmacovigilence activities. As chair of the Global Safety Board, she was also responsible for ensuring patient, clinical trial and product safety. Other positions include serving as group director, Global Clinical Research, Virology and Infections Diseases at Bristol-Myers Squibb, and head of Clinical Drug Discovery Virology at GlaxoSmithKline.

“Janet’s background and experience will be a great addition to our efforts to drive Translational Medicine as well as Virology within Roche as we continue our quest to find new and more effective approaches to drug development, ultimately providing better options for patients,” said Dr. Banchereau.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters